Series date: 
01/01/2023 - 7:30am to 12/31/2023 - 7:30am

DESCRIPTION
This series is held weekly on Friday, 7:30 - 8:30 a.m.

Consultants, fellows and visiting professors present a 45 minute discussion topic which is intended to be a comprehensive review after which there is a 10-15 minute period for questions.  These "state-of-the-art" lectures are directed at the faculty and fellow level.  

TARGET AUDIENCE
The audience is primarily the physicians in our division, but all members of the division, i.e. nurses, NP/PAs and allied health staff are encouraged to attend.  Other areas/divisions are allowed to attend if they wish.  

LEARNING OBJECTIVES
Upon conclusion of this program, participants should be able to:

  • Describe how to apply clinical practice updates to improve patient outcomes.

  • Critically review clinical and basic research literature using an evidence-based approach.

  • Debate if specific findings are relevant and applicable to patient care.

Accreditation Statement
In support of improving patient care, Mayo Clinic College of Medicine and Science is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



Credit Statement(s): 
AMA
Mayo Clinic College of Medicine and Science designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Summary
As a provider accredited by Joint Accreditation for Interprofessional Continuing Education, Mayo Clinic College of Medicine and Science must ensure balance, independence, objectivity and scientific rigor in its educational activities.  All who are in a position to control the content are required to disclose all financial relationships with any ineligible company.   Faculty will also identify any off-label and/or investigational use of pharmaceuticals or instruments discussed in their content for FDA compliance.

Listed below are individuals with control of the content of this program who have disclosed...

Relevant financial relationship(s) with ineligible companies: 
Hatem Amer, M.D. - Grant/Research Support - Kaneka Pharma
 
All relevant financial relationships listed for these individuals have been mitigated.

No relevant financial relationship(s) with ineligible companies: 
Iasmina M. Craici, M.D.; Ladan Zand, M.D.; Melissa L. Hanson, Jacqlyn (Jackie) A. Oakland, Kathy Hegna Zelinske
 
References to off-label usage(s) of pharmaceuticals or instruments in their presentation:
None

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s), please go here. 

ATTENDANCE/CREDIT
Text the session code (provided only at the session) to 507-200-3010image within 48 hours of the live presentation to record attendance.  All learners are encouraged to text attendance regardless of credit needs.  This number is only used for receiving text messages related to tracking attendance.  Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows. 

TRANSCRIPT
Any credit or attendance awarded from this series will appear on your Transcript.

COURSE DIRECTORS
Ladan Zand, M.D. and Iasmina Craici, M.D.

QUESTIONS?
Contact Kathy Hegna Zelinske at phone 6-1044 OR Jacqlyn Oakland at phone 4-3479

*Required Information for Accreditation is posted in Outlook Calendar Invitation.
Support location: 
Minnesota

Sessions

Session Date
(Nephrology Hypertension Journal Club) Optimized Immunosuppression to prevent graft failure in renal transplant recipients with HLA antibodies: April 21, 2023 04/21/2023 - 7:30am to 8:30am
(Nephrology Hypertension Journal Club) Sparsentan in Patients with IgA nephropathy: a prespecified interim analysis from a randomized, double-blind, active-controlled clinical trial: April 28, 2023 04/28/2023 - 7:30am to 8:30am
(Nephrology Hypertension Journal Club) Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 Variants 05/05/2023 - 7:30am to 8:30am
Nephrology Hypertension Journal Club: Genetic Variation, Coffee Intake, and Kidney Dysfunction (May 19, 2023) 05/19/2023 - 7:30am to 8:30am
Nephrology Hypertension Journal Club Comparing Physician and Artificial Intelligence Chatbot Responses to Patient Questions Posted to a Public Social Media Forum : May 26, 2023 05/26/2023 - 7:30am to 8:30am
Nephrology Hypertension Journal Club Heterogeneity in Blood Pressure Response to 4 Antihypertensive Drugs A Randomized Clinical Trial : June 2, 2023 06/02/2023 - 7:30am to 8:30am
Nephrology Hypertension Journal Club : Endovascular Ultrasound Renal Denervation to Treat Hypertension 06/16/2023 - 7:30am to 8:30am
Nephrology Hypertension Journal Club Antibody-Guided Therapy in Phospholipase A2 Receptor Associated Membranous Nephropathy June 23, 2023 06/23/2023 - 7:30am to 8:30am
Nephrology Hypertension Journal Club : Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence July 30, 2023 06/30/2023 - 7:30am to 8:30am
Nephrology Hypertension Journal Club : Sodium bicarbonate for kidney transplant recipients with metabolic acidosis in Switzerland: a multicentre, randomized, single-blind, placebo-controlled, phase 3 trial (July 7, 2023) 07/07/2023 - 7:30am to 8:30am

Pages